Pegzilarginase is a medicine for arginase 1 deficiency, a rare inherited condition where a substance called arginine builds up in the blood. It is given as an infusion into a vein or as a shot under the skin. It is a man-made copy of the missing enzyme that breaks down arginine.
Every report comes from a Lived member, sent anonymously.
Have you tried Loargys (Pegzilarginase) for Argininemia?
Pegzilarginase, sold as Loargys, is an enzyme replacement treatment for arginase 1 deficiency (ARG1-D), a rare inherited condition in which the body cannot properly break down the amino acid arginine. Arginine then builds up in the blood and tissues. Over years, this typically causes stiffness and tightness in the leg muscles (spasticity) that makes walking and climbing stairs harder, and some people also have developmental delay, learning difficulties or seizures. In the US, Loargys is approved for adults and children 2 years and older with ARG1-D. It is used together with a protein-restricted diet, not in place of it. The diet limits how much arginine comes in from food, but the body also makes arginine itself, which is why diet alone rarely brings levels down far enough. The approval is an accelerated approval, granted because the medicine reliably lowers blood arginine. Whether that translates into better walking, less stiffness or slower progression is still being confirmed in further study. It has not been established for children under 2.
Arginase 1 is the enzyme that normally performs the final step of the urea cycle, the liver's process for clearing excess nitrogen from protein. It splits arginine into urea, which leaves the body in urine, and ornithine, which the cycle reuses. In ARG1-D the enzyme does not work, so arginine and related compounds accumulate and are thought to damage the nervous system over time. Pegzilarginase is a lab-made version of the human arginase 1 enzyme. Given by injection, it circulates in the blood and does the missing job there, converting arginine into urea and ornithine. The enzyme is attached to polyethylene glycol (PEG), a coating that keeps it in the body longer, which is what allows dosing once a week.
Loargys is given once a week, with the dose based on body weight. Treatment begins as an infusion into a vein (IV) of at least 30 minutes, in a clinic or hospital setting with staff and equipment ready to treat a severe allergic reaction. The care team may give an antihistamine beforehand. The dose is fine-tuned using blood arginine levels measured just before a weekly dose. The aim is to keep arginine in the normal range, roughly 40 to 115 micromoles per liter (micromolar), ideally near its upper end; levels below about 50 suggest the dose can come down, and levels above about 150 suggest it should go up. These samples must be collected in special tubes and run on a specific test, and in the US the medicine is currently provided only to people enrolled in the manufacturer's program for that testing (study IMM-PEG-005). After eight weeks of IV treatment, many people can switch to a weekly injection under the skin of the belly, thigh or upper arm at the same dose. If that goes well, injections may be given at home under a care team's supervision. A missed dose is given as soon as possible, with at least four days between doses. If a home dose is missed or delayed, contact the care team, because the next injections may need to be given in a supervised setting.
In the main trial, the most common side effects were vomiting, fever, constipation and reactions during or shortly after an infusion, such as itching, arm swelling or stomach pain. People who switch to injections under the skin may notice pain, redness, swelling or a rash at the injection site. Allergic reactions are the main concern. In trials, about 1 in 8 people had a mild to moderate reaction, such as facial swelling, rash, flushing or shortness of breath, usually with the first few doses. Loargys also carries the FDA's most serious (boxed) warning about life-threatening allergic reactions, including anaphylaxis, which can happen early in treatment or after a long time on it. Trouble breathing, swelling of the lips, tongue or throat, or feeling faint after a dose needs emergency care right away: call 911 if this happens at home. Milder reactions should be reported to the care team, who may adjust premedication, slow the infusion or change where doses are given.
No drug interactions are listed in the prescribing information, but the care team should still know about every medicine and supplement being taken, including ammonia-lowering medicines and amino acid supplements used for the condition. The body can make antibodies against pegzilarginase or its PEG coating. In studies, people with high levels of these antibodies tended to have more allergic reactions and smaller drops in arginine, which is one reason regular blood tests continue. Anyone who has had a severe reaction will need a careful discussion before treatment is restarted. There is no information on use during pregnancy or breastfeeding in people. Animal studies at high doses showed harm to the mother and slower growth in the young, so anyone pregnant, planning a pregnancy or breastfeeding should talk through the balance of risks with the specialist team.
Blood arginine usually falls quickly. In the trial that led to approval, levels dropped by about three quarters on average within 24 weeks, and 9 in 10 people reached the normal range, compared with none on placebo. Before treatment, most participants had levels several times above normal despite following their diet. Changes in walking and stiffness, if they come, develop more slowly. In longer open-label follow-up, lasting up to three to five years, most participants showed better results on walking tests and less spasticity. Those studies had no comparison group, and the FDA is still waiting on confirmatory evidence, so how much any one person improves is uncertain. Treatment is ongoing, with weekly doses, regular arginine checks and continued care from a metabolic specialist and dietitian. The protein-restricted diet stays in place alongside the medicine.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Loargys (Pegzilarginase), what you've noticed, or ask the community a question.